health ACTIV-6 Trial: Metformin Reduces Clinician-Diagnosed Long COVID Risk
The ACTIV-6 randomized trial reveals metformin lowers clinician-diagnosed long COVID by 50% in immune outpatients, despite missing primary endpoints for patient-reported symptom prevention at six months.
